SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...
To present the pioneering concept, Peer and his team encoded the anti-inflammatory protein interleukin-10 into mRNA and ...
For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major ...
Low-fiber fruits and vegetables, lean proteins, and foods rich in omega-3 fatty acids tend to be easier on an inflamed gut, ...
Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel ...
Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The ...
3d
Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without ...
JACK FITZWATER has revealed how he thought his football career was in jeopardy when he was forced to visit the toilet 40 times a day. The defender hopes to help League One club Exeter topple ...
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Omvoh works to reduce inflammation within the gastrointestinal ...
Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active ...
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...
Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback